Natco Pharma Ltd (NSE: NATCOPHARM, BSE: 524816) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹14,061 Cr, it ranks #487 by market cap among the 6,137 Indian listed companies on FinBizNet, and #19 of 86 in Medicinal Chemicals and Botanical Products. At ₹791.85 (as of 25 Oct 2026), the share price is 35.5% below its 52-week high of ₹1,226.80 and 2.4% above its 52-week low of ₹773.60. The share price is down 3.7% over one year and down 14.1% over three months.
| Current Price | ₹791.85 |
|---|---|
| Market Cap | ₹14,061 Cr |
| NSE Symbol | NATCOPHARM |
| BSE Code | 524816 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 10.1 |
| Return on Equity | 16.85% |
| Return on Assets | 7.98% |
| 52-Week Range | ₹773.60 – ₹1,226.80 |
| 1-Year Price Change | -3.7% |
| 3-Month Price Change | -14.1% |
| Beta (1Y) | 0.23 |
| Dividend Yield | 0.56% |
| Headquarters | Hyderabad, Telangana |
| Website | www.natcopharma.co.in |
| Revenue | ₹735 Cr |
|---|---|
| Net Profit | ₹122 Cr |
| Net Margin | 16.6% |
| EPS (Basic) | ₹11.53 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of i
1. Pharmaceuticals-This segment develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients. 2. Agro Chemicals-This segment offers agro chemicals. 3. Unallocated-0 4. Segment Adjustment-0
1. Pharmaceuticals-96.6% 2. Agro Chemicals-3.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Natco Pharma Ltd | ₹14,061 Cr | 10.1 | 16.85% | ₹735 Cr | -3.7% |
Listed by market capitalisation. Ratios are shown for context only.
Natco Pharma Ltd is trading at ₹791.85, with a market capitalisation of ₹14,061 Cr.
Natco Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Natco Pharma Ltd has a P/E of 10.1 and a return on equity of 16.85%.
Natco Pharma Ltd is listed on the NSE under the symbol NATCOPHARM and on the BSE under the scrip code 524816.
Natco Pharma Ltd's share price is down 3.7% over one year and down 14.1% over three months. Its 52-week range is ₹773.60 to ₹1,226.80.
In Q1 FY27, Natco Pharma Ltd reported revenue of ₹735 Cr and net profit of ₹122 Cr, with basic EPS of ₹11.53 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.